Systemair AB
Press Release, 2 March 2021
Systemair ABs (NASDAQ OMX Stockholm: SYSR) Interim Report Q3 for the financial year 2020/21 will be published at 08:00 CET on March 11, 2021.
A telephone conference will be held at 09:00 CET on March 11, 2021. The report will be presented by Roland Kasper, CEO, and Anders Ulff, CFO.
In order to participate in the telephone conference:
Call +46 8 566 426 51 and enter code 72599017# minutes before start.
The presentation will be published on group.systemair.com
For further information contact:
Roland Kasper, CEO, + 46 73 094 40 13
Anders Ulff, CFO, + 46 70 577 40 09
Systemair AB, SE-739 30 Skinnskatteberg, Sweden, +46 222 440 00, www.systemair.com
Systemair in brief
Systemair is a leading ventilation company with operations in 50 countries in Europe, North America, South America, the Middle East, Asia, Australia and Africa. The Company had sales of SEK 8.9 billion in the 2019/20 financial year and employs approximately 6,200 people. Systemair has reported an operating profit every year since 1974, when the company was founded. Over the past 10 years, the Company's growth rate has averaged about 11 percent. Systemair contributes to enhance the indoor environment with energy efficient and sustainable products that reduce carbon dioxide emissions.
Systemair has well-established operations in growth markets. The Group's products are marketed under the Systemair, Frico, Fantech and Menerga brands. Systemair shares have been quoted on the Mid Cap List of the Nasdaq OMX Nordic Exchange in Stockholm since October 2007. The Group comprises about 80 companies.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Evaxion17.10.2025 14:15:51 CEST | Press release
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
WillScot17.10.2025 14:00:00 CEST | Press release
WillScot Closes Amended and Extended Asset-Based Revolving Credit Facility
Novartis Pharma AG17.10.2025 14:00:00 CEST | Press release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
Sanofi Winthrop Industrie17.10.2025 13:05:00 CEST | Press release
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Sanofi Winthrop Industrie17.10.2025 13:00:00 CEST | Press release
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom